a-LEN-drone-ate 
Contraindicated in:
Use Cautiously in:
CV: atrial fibrillation.
Derm: erythema, photosensitivity, rash.
EENT: blurred vision, conjunctivitis, eye pain/inflammation.
GI: abdominal distention, abdominal pain, acid regurgitation, constipation, diarrhea, dyspepsia, dysphagia, esophageal cancer, esophageal ulcer, esophagitis, flatulence, gastritis, nausea, taste perversion, vomiting.
MS: musculoskeletal pain, femur fractures, osteonecrosis (primarily of jaw).
Neuro: headache.
Resp: asthma exacerbation.
Drug-Drug:
Drug-Food:
(Generic available)
Treatment of Osteoporosis
Prevention of Osteoporosis
Treatment of Corticosteroid-Induced Osteoporosis in Men and Women
Absorption: Poorly absorbed (0.6–0.8%) after oral administration.
Distribution: Transiently distributes to soft tissue, then distributes to bone.
Metabolism/Excretion: Excreted in urine.
Half-life: 10 yr (reflects release of drug from skeleton).
(inhibition of bone resorption)
| ROUTE | ONSET | PEAK | DURATION |
|---|---|---|---|
| PO | 1 mo | 3–6 mo | 3 wk–7 mo† |
†After discontinuation of alendronate.
NDC Code*
